Meet the Chetty Lab
Dr. Chetty started her lab at Stanford University after completing her post-doctoral work in Stem Cell and Regenerative Biology at Harvard University in Douglas Melton’s laboratory. She received her Ph.D. in neuroscience and B.A. in molecular and cell biology from the University of California, Berkeley. Her lab seeks to utilize human pluripotent stem cells to treat and model neuropsychiatric disorders.
Jingling joined the Chetty lab in March 2017 after completing her PhD in the department of Biological Sciences at the University of Notre Dame. She is broadly interested in the therapeutic applications of stem cells for regenerative medicine. Her current work focuses on investigating the role of glial cells in neurological and psychiatric disorders using human pluripotent stem cells.
Thomas joined the Chetty lab in May 2017 after completing his PhD in the department of Regenerative Medicine at Virginia Tech. He is broadly interested in using stem cell biology to model and understand neuropsychiatric disorders. His current work focuses on investigating the neural mechanisms underlying psychiatric disorders using human induced pluripotent stem cells.
Cyndhavi joined the Chetty lab in January 2016 after working as a research assistant in Ravindra Majeti’s laboratory at Stanford University for 6 years. She completed her M.S. in molecular biology from the University of Southern California in Los Angeles and her B.Tech in Biotechnology from Anna University in India. She is currently investigating the epigenetic mechanisms controlling human pluripotent stem cell differentiation.
Jing joined the Chetty lab in June 2016 after working as a visiting scientist at the Jiangsu Key Laboratory of Neuroregeneration at Nantong University in China. She completed her postdoctoral fellowship in the department of Stem Cell and Regenerative Medicine at the Cleveland Clinic and her Ph.D. in Biomedical Engineering at the Cleveland Clinic in Ohio. She is currently investigating the role of glial cells in psychiatric disorders using human pluripotent stem cells.